Comparative bioinformatic analysis of KRAS, STK11 and KEAP1 (co-)mutations in non-small cell lung cancer with a special focus on KRAS G12C.
Humans
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Proto-Oncogene Proteins p21(ras)
/ genetics
Kelch-Like ECH-Associated Protein 1
/ genetics
Lung Neoplasms
/ drug therapy
NF-E2-Related Factor 2
/ genetics
Mutation
/ genetics
Computational Biology
Protein Serine-Threonine Kinases
/ genetics
AMP-Activated Protein Kinase Kinases
Journal
Lung cancer (Amsterdam, Netherlands)
ISSN: 1872-8332
Titre abrégé: Lung Cancer
Pays: Ireland
ID NLM: 8800805
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
25
07
2023
accepted:
04
09
2023
medline:
19
9
2023
pubmed:
12
9
2023
entrez:
12
9
2023
Statut:
ppublish
Résumé
Mutations in STK11 (STK11 We present a comprehensive bioinformatic analysis encompassing six datasets retrieved from cBioPortal. Independent of the treatment, triple mutations and STK11 The triple mutation status may serve as a negative prognostic and predictive factor across treatments compared to KRAS
Identifiants
pubmed: 37699269
pii: S0169-5002(23)00899-1
doi: 10.1016/j.lungcan.2023.107361
pii:
doi:
Substances chimiques
Proto-Oncogene Proteins p21(ras)
EC 3.6.5.2
Kelch-Like ECH-Associated Protein 1
0
NF-E2-Related Factor 2
0
Protein Serine-Threonine Kinases
EC 2.7.11.1
KRAS protein, human
0
KEAP1 protein, human
0
STK11 protein, human
EC 2.7.11.1
AMP-Activated Protein Kinase Kinases
EC 2.7.11.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
107361Informations de copyright
Copyright © 2023 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.